Works matching AU Shetty, Jeevan K.

Results: 15
    1
    2

    Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.

    Published in:
    Journal of Clinical Medicine, 2022, v. 11, n. 1, p. 27, doi. 10.3390/jcm11010027
    By:
    • Oliva, Esther Natalie;
    • Platzbecker, Uwe;
    • Garcia-Manero, Guillermo;
    • Mufti, Ghulam J.;
    • Santini, Valeria;
    • Sekeres, Mikkael A.;
    • Komrokji, Rami S.;
    • Shetty, Jeevan K.;
    • Tang, Derek;
    • Guo, Shien;
    • Liao, Weiqin;
    • Zhang, George;
    • Ha, Xianwei;
    • Ito, Rodrigo;
    • Lord-Bessen, Jennifer;
    • Backstrom, Jay T.;
    • Fenaux, Pierre
    Publication type:
    Article
    3
    4
    5
    6

    PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE‐BLIND, RANDOMIZED, PLACEBO‐CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA‐THALASSEMIA.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000976836.19231.b2
    By:
    • Viprakasit, Vip;
    • Lai, Yongrong;
    • Forni, Gian Luca;
    • Lu, Meng‐Yao;
    • Yang, Liudi;
    • Shi, Wenhui;
    • Medlin, Loyse Felber;
    • Lersch, Frederik;
    • Shetty, Jeevan K.;
    • Bueno, Luciana Moro;
    • Wei, Richard;
    • Kattamis, Antonis
    Publication type:
    Article
    7
    8

    S273: LONG‐TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON‐TRANSFUSION‐DEPENDENT ΒETA‐THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000968004.45673.ef
    By:
    • Taher, Ali T.;
    • Viprakasit, Vip;
    • Domenica Cappellini, Maria;
    • Giulio Piga, Antonio;
    • Porter, John B.;
    • Coates, Thomas D.;
    • Musallam, Khaled M.;
    • Luca Forni, Gian;
    • Shetty, Jeevan K.;
    • Bosilkovska Weisskopf, Marija;
    • Wei, Richard;
    • Kuo, Wen‐Ling;
    • Kattamis, Antonis
    Publication type:
    Article
    9

    S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA‐NAIVE LOWER‐RISK MYELODYSPLASTIC SYNDROMES (LR‐MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967316.99954.0c
    By:
    • Della Porta, Matteo Giovanni;
    • Platzbecker, Uwe;
    • Santini, Valeria;
    • Zeidan, Amer M.;
    • Fenaux, Pierre;
    • Komrokji, Rami S.;
    • Shortt, Jake;
    • Valcárcel, David;
    • Jonášová, Anna;
    • Dimicoli‐Salazar, Sophie;
    • Tiong, Ing Soo;
    • Lin, Chien‐Chin;
    • LI, Jiahui;
    • Zhang, Jennie;
    • Carolina Giuseppi, Ana;
    • Kreitz, Sandra;
    • Pozharskaya, Veronika;
    • Keeperman, Karen L.;
    • Rose, Shelonitda;
    • Shetty, Jeevan K.
    Publication type:
    Article
    10
    11
    12
    13
    14
    15

    Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.

    Published in:
    European Journal of Haematology, 2023, v. 111, n. 1, p. 113, doi. 10.1111/ejh.13975
    By:
    • Cappellini, Maria Domenica;
    • Taher, Ali T.;
    • Piga, Antonio;
    • Shah, Farrukh;
    • Voskaridou, Ersi;
    • Viprakasit, Vip;
    • Porter, John B.;
    • Hermine, Olivier;
    • Neufeld, Ellis J.;
    • Thompson, Alexis A.;
    • Tang, Derek;
    • Yucel, Aylin;
    • Lord‐Bessen, Jennifer;
    • Yu, Peiwen;
    • Guo, Shien;
    • Shetty, Jeevan K.;
    • Miteva, Dimana;
    • Zinger, Tatiana;
    • Backstrom, Jay T.;
    • Oliva, Esther Natalie
    Publication type:
    Article